Phase 3 results probably get announced Q4 19' or Q1 20'? If enrollment completes by end summer, then 11 month test and at least 1 quarter to analyze and report.
The good news about engagement in RTT is that there'll be leakage of (hopefully) efficacy from those being treated during that time.
The best news of course will be buzz from entering into agreements with funding disease institutions for the much larger indications.
So long as all the patients are requesting to stay in the tests, and have them extended, that is proof enough for me.
The cream on the top, will be if Israel approves procedures and a flood of paying customers comes I from the EU for treatment in the relatively short term. That will bring in dollars, and make this a 'real' company, not a spec biotech, in 2019.
If these things happen, yes, no problem with $1B in 2019 ($50/share), and if they're funded for 2 more indications, then $75. Andlets not think about ALZ unless they get further proof of efficacy....then the roof gets blown off. But I have been disappointed before with PRANA, and now with AVXL, so this is not a done deal.
News 
Market Data 
Discover 
